Last reviewed · How we verify
Amsalog (asulacrine)
Amsalog (generic name: asulacrine) is a asulacrine drug. It is currently in unknown development.
Amsalog works by blocking the enzyme DNA topoisomerase 2-alpha, which is essential for DNA replication and repair.
Amsalog is a small molecule. It is also known by other names, including Asulacrine, CI-921, NSC 343499, and SN-21407.
At a glance
| Generic name | asulacrine |
|---|---|
| Drug class | asulacrine |
| Target | DNA topoisomerase 2-alpha |
| Therapeutic area | Oncology |
| Phase | unknown |
Mechanism of action
Imagine your DNA is a long, twisted ladder. DNA topoisomerase 2-alpha is like a special tool that helps untwist the ladder so that the DNA can be copied. Amsalog blocks this tool, which can prevent cancer cells from growing and dividing.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amsalog CI brief — competitive landscape report
- Amsalog updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Amsalog
What is Amsalog?
How does Amsalog work?
What is the generic name of Amsalog?
What drug class is Amsalog in?
What development phase is Amsalog in?
What does Amsalog target?
Related
- Drug class: All asulacrine drugs
- Target: All drugs targeting DNA topoisomerase 2-alpha
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Oncology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing